Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA 2 continuation study of Orelvo in lupus nephritis
NL-OMON50319Phase 3Completed
- Sponsor
- Aurinia
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Orelvo continuation arm with Placebo continuation arm (2 arms). Primary endpoint: Long-term safety and tolerability. Started Oct 2018; status: completed.
02
Drugs
voclosporin
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NL-OMON50319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50319.